Trial
NCT04849715
A Study of Parsaclisib, a PI3Kδ Inhibitor, in Combination With Bendamustine and Rituximab in Patients With Newly Diagnosed Mantle Cell Lymphoma
Phase IIIWITHDRAWNOPERATIONALConfidence: HIGH
Sponsor
Incyte Corporation
Collaborators
—
Condition
Mantle Cell Lymphoma
Intervention
parsaclisib
Why stopped
business decision; no enrolled patients
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2022-04-29